ATE310537T1 - Kombinationstherapie von angiotensin- konvertierendem enzymhemmer und epoxy-steroidalem aldosteron antagonist zur behandlung von kardiovaskulären erkrankungen - Google Patents

Kombinationstherapie von angiotensin- konvertierendem enzymhemmer und epoxy-steroidalem aldosteron antagonist zur behandlung von kardiovaskulären erkrankungen

Info

Publication number
ATE310537T1
ATE310537T1 AT03019610T AT03019610T ATE310537T1 AT E310537 T1 ATE310537 T1 AT E310537T1 AT 03019610 T AT03019610 T AT 03019610T AT 03019610 T AT03019610 T AT 03019610T AT E310537 T1 ATE310537 T1 AT E310537T1
Authority
AT
Austria
Prior art keywords
epoxy
treatment
combination therapy
cardiovascular diseases
converting enzyme
Prior art date
Application number
AT03019610T
Other languages
English (en)
Inventor
John C Alexander
Barbara Roniker
Subhash Desai
Original Assignee
Searle Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle Llc filed Critical Searle Llc
Application granted granted Critical
Publication of ATE310537T1 publication Critical patent/ATE310537T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Wood Science & Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Vascular Medicine (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
AT03019610T 1999-03-05 2000-03-03 Kombinationstherapie von angiotensin- konvertierendem enzymhemmer und epoxy-steroidalem aldosteron antagonist zur behandlung von kardiovaskulären erkrankungen ATE310537T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12297799P 1999-03-05 1999-03-05

Publications (1)

Publication Number Publication Date
ATE310537T1 true ATE310537T1 (de) 2005-12-15

Family

ID=22406014

Family Applications (2)

Application Number Title Priority Date Filing Date
AT03019610T ATE310537T1 (de) 1999-03-05 2000-03-03 Kombinationstherapie von angiotensin- konvertierendem enzymhemmer und epoxy-steroidalem aldosteron antagonist zur behandlung von kardiovaskulären erkrankungen
AT00912174T ATE249242T1 (de) 1999-03-05 2000-03-03 Kombinationstherapie von angiotensin- konvertierendem enzym hemmer und epoxy- steroidalem aldosteron antagonist zur behandlung von kardiovaskulären erkrankungen

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT00912174T ATE249242T1 (de) 1999-03-05 2000-03-03 Kombinationstherapie von angiotensin- konvertierendem enzym hemmer und epoxy- steroidalem aldosteron antagonist zur behandlung von kardiovaskulären erkrankungen

Country Status (24)

Country Link
US (1) US20040077611A1 (de)
EP (2) EP1382351B8 (de)
JP (1) JP2002538172A (de)
KR (1) KR100580286B1 (de)
CN (1) CN1229141C (de)
AR (1) AR029155A1 (de)
AT (2) ATE310537T1 (de)
AU (2) AU778559B2 (de)
BR (1) BR0008781A (de)
CA (1) CA2364169A1 (de)
DE (2) DE60024335T2 (de)
DK (2) DK1382351T3 (de)
EA (1) EA004064B1 (de)
ES (2) ES2250803T3 (de)
HK (2) HK1042252B (de)
HU (1) HUP0200519A2 (de)
IL (2) IL145237A0 (de)
MX (1) MXPA01009035A (de)
NZ (1) NZ514205A (de)
PT (1) PT1165136E (de)
SI (1) SI1165136T1 (de)
TR (1) TR200102581T2 (de)
WO (1) WO2000051642A1 (de)
ZA (1) ZA200107779B (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001041535A2 (en) * 1999-12-08 2001-06-14 Pharmacia Corporation Eplerenone crystalline form
EP1580193A3 (de) * 1999-12-08 2010-06-23 Pharmacia Corporation Kristalline Form von Eplerenon
AU784946B2 (en) * 1999-12-08 2006-08-03 Pharmacia Corporation Eplerenone crystalline form exhibiting enhanced dissolution rate
EP1505072A3 (de) * 1999-12-08 2006-06-21 Pharmacia Corporation Kristalline Form von Eplerenon mit verbesserter Lösegeschwindigkeit
AU2001255730A1 (en) * 2000-04-26 2001-11-07 First Horizon Pharmaceutical Corporation Methods and compositions for the treatment of cardiac indications
US20020111337A1 (en) * 2000-08-28 2002-08-15 Fedde Kenton N. Use of an aldosterone receptor antagonist to improve cognitive function
WO2006119779A2 (en) * 2005-05-10 2006-11-16 Lifecycle Pharma A/S A pharmaceutical composition comprising an aldosterone antagonist in form of solid solution
US20100028439A1 (en) * 2005-05-23 2010-02-04 Elan Pharma International Limited Nanoparticulate stabilized anti-hypertensive compositions
US20070112593A1 (en) * 2005-11-14 2007-05-17 Rxcera Pharmaceutical, Inc. Selection system, dispensing system and treatment with a one-a-day combination pill for hypertension, hypercholesterolemia, hypertriglyceridemia and anti-platelet treatment
US20100318371A1 (en) * 2009-06-11 2010-12-16 Halliburton Energy Services, Inc. Comprehensive hazard evaluation system and method for chemicals and products
WO2014018930A1 (en) * 2012-07-27 2014-01-30 Isis Pharmaceuticals. Inc. Modulation of renin-angiotensin system (ras) related diseases by angiotensinogen
CN106267147A (zh) * 2015-06-10 2017-01-04 上药东英（江苏）药业有限公司 一种复方降压药物组合物
BR112018005223B1 (pt) 2015-10-08 2022-08-09 Ionis Pharmaceuticals, Inc Compostos, uso dos mesmos, e composição farmacêutica
IL302817A (en) 2020-11-18 2023-07-01 Ionis Pharmaceuticals Inc Compounds and methods for modulating angiotensinogen expression

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040255A2 (en) * 1995-06-07 1996-12-19 G.D. Searle & Co. Method to treat cardiofibrosis with a combination therapy of an angiotensin ii antagonist and an epoxy-steroidal aldosterone antagonist
ES2167571T3 (es) * 1995-06-07 2002-05-16 Searle & Co Terapia de combinacion de antagonista de aldosterona epoxi-esteroideo y antagonista de angiotensina ii para el tratamiento del fallo cardiaco congestivo.

Also Published As

Publication number Publication date
MXPA01009035A (es) 2004-08-12
IL145237A (en) 2006-08-01
DE60005159D1 (de) 2003-10-16
HK1042252A1 (en) 2002-08-09
EP1382351A1 (de) 2004-01-21
DK1165136T3 (da) 2004-01-12
CN1229141C (zh) 2005-11-30
AU3394500A (en) 2000-09-21
ES2250803T3 (es) 2006-04-16
BR0008781A (pt) 2002-07-02
EP1165136B1 (de) 2003-09-10
NZ514205A (en) 2004-07-30
EP1382351B1 (de) 2005-11-23
AU2005201045A1 (en) 2005-04-07
JP2002538172A (ja) 2002-11-12
EP1165136A1 (de) 2002-01-02
CA2364169A1 (en) 2000-09-08
PT1165136E (pt) 2004-02-27
HK1061200A1 (en) 2004-09-10
DE60024335D1 (de) 2005-12-29
KR20010108319A (ko) 2001-12-07
WO2000051642A1 (en) 2000-09-08
ES2206204T3 (es) 2004-05-16
HK1042252B (zh) 2004-04-23
IL145237A0 (en) 2002-06-30
TR200102581T2 (tr) 2002-04-22
DK1382351T3 (da) 2006-01-23
EA200100951A1 (ru) 2002-04-25
DE60024335T2 (de) 2006-08-03
HUP0200519A2 (hu) 2002-07-29
US20040077611A1 (en) 2004-04-22
AR029155A1 (es) 2003-06-18
KR100580286B1 (ko) 2006-05-16
SI1165136T1 (en) 2004-02-29
ZA200107779B (en) 2002-12-20
AU778559B2 (en) 2004-12-09
EP1382351B8 (de) 2006-03-08
EA004064B1 (ru) 2003-12-25
ATE249242T1 (de) 2003-09-15
CN1372475A (zh) 2002-10-02
DE60005159T2 (de) 2004-07-22

Similar Documents

Publication Publication Date Title
ATE527022T1 (de) Verwendung von cyclooxygenase-2-inhibitoren zur behandlung und vorbeugung von tumoren, von tumor- abhängigen erkrankungen und kachexie
DE602004010407D1 (de) Fluorsubstituierter omega-carboxyaryldiphenylharnstoff zur behandlung und prävention von krankheiten und leiden
ATE417602T1 (de) Mittel zur behandlung von erkrankungen der speiseröhre
ATE434444T1 (de) Vorbeugung und behandlung von amyloidogenischen krankheiten
ATE310537T1 (de) Kombinationstherapie von angiotensin- konvertierendem enzymhemmer und epoxy-steroidalem aldosteron antagonist zur behandlung von kardiovaskulären erkrankungen
DE60037394D1 (de) VERWENDUNG VON p53 INHIBITOREN ZUR BEHANDLUNG VON NEBENERSCHEINUNGEN BEI DER KREBSTHERAPIE
DE60324777D1 (de) Verwendung von il-18-inhibitoren zur behandlung und/oder prävention von peripheren gefässkrankheiten
ATE357440T1 (de) Benzodiazepin-substituierte piperdine zur verwendung in der behandlung von cardiovaskulären erkrankungen
DE60224163D1 (de) Kombinationen von ezetimibe und aspirin zur behandlung von kardiovaskulären erkrankungen
ATE358117T1 (de) Adamantanderivate zur behandlung von entzündlichen, immunologischen und kardiovaskulären erkrankungen
DE60223694D1 (de) Pflaster zur behandlung von funktionsstörungen und störungen des nagelwachstums
ATE369851T1 (de) Kombinationen von gallensäuresequestriermitteln und hemmern der sterolabsorption zur behandlung von kardiovaskulären indikationen
NO20030761D0 (no) Farmasöytisk kombinasjon av angiotensin II antagonister og angiotensin I konverterende enzyminhibitorer
ATE295174T1 (de) Arzneimittel zur behandlung von bluthochdruck
DE50114605D1 (de) No-thien-2-yl-essigsaure-derivate und ihre verwendung zur behandlung von migraine bzw. schmerz
ATE385789T1 (de) Verwendung von einem aldosteronantagonist zur behandlung und vorbeugung von aldosteron- vermittelten pathogenen zuständen
DE60224004D1 (de) Verwendung von il-18 hemmern zur behandlung und/oder prävention von herzkrankheiten
DE60122898D1 (de) Aldosteronantagonist und cyclooxygenase-2 hemmer-kombinationstherapie zur verhinderung oder behandlung von entzündungsverwandten kardiovaskulären krankheiten
DE60018200D1 (de) Verwendung von pleuromutilinderivaten zur transdermalen behandlung bakterieller erkrankungen
DE69813083D1 (de) Kombination in feste Dosiermenge von Angiotensin-Converting-Enzyme-Hemmern mit Calcium-Kanal Antagonisten zur Behandlung von Herz-Kreislauferkrankungen
ATE295724T1 (de) Der duale inhibitor der cholesterylester und wachsester synthese avasimibe zur behandlung von erkrankungen des talgdrüse
DE60203878D1 (de) Verfahren zur vorbeugung gegen und behandlung von unterleibsschmerzen und magen-darmerkrankungen
ATE314064T1 (de) L-acetylcarnitin und l-propionylcarnitin zusammensetzung zur verhütung und behandlung von nierenstörungen und nierenenkrankheit
DE60036723D1 (de) Mesoprogestine zur behandlung und vorbeugung von hormonabhängigen gutartigen gynekologischen störungen
DE60215060D1 (de) Kräuterpräparat zur behandlung von herz-kreislauf- sowie neurologischen erkrankungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1382351

Country of ref document: EP

REN Ceased due to non-payment of the annual fee